Skip to main content
. 2016 Nov 21;9(1):28–35. doi: 10.1177/1756287216677903

Table 1.

Observations reporting on clinical outcome of VFL in daily clinical practice since the drug’s approval in 2009.

Author Number of observed patients OS/PFS (months)
Pistamaltzian et al. [2016] n = 71, retrospective study 11.9/6.9
Moriceau et al. [2015] n = 19, retrospective study 4.0/2.9
Medioni et al. [2016] n = 134, retrospective study 8.2/4.2
Hegele et al. [2014] n = 21, retrospective study 6.2/4.4
Retz et al. [2015] n = 77, prospective study 7.7/–
Castellano et al. [2014] n = 102, prospective study 10.0/3.9
Palacka et al. [2014] n = 16, prospective study 5.2/2.3
Summarized n = 440, prospective and retrospective observations 7.6/4.1
Bellmunt et al. [2009] n = 259, phase III trial 6.9/3.0

OS, overall survival; PFS, progression-free survival.